Abstract: The present invention relates to a transparent or semitransparent cosmetic composition in which the stability of amentoflavone is enhanced, and more particularly, to a transparent or semitransparent cosmetic composition, wherein a water-soluble amentoflavone-oligomer complex, in which amentoflavone is encapsulated in a hollow structure of an oligomer structure, is stabilized in a second agent containing a polyhydric alcohol, a two-liquid-type container is used to mix first and second agents before use, and hydrotrope is contained in the first agent to increase the mixing stability of the first and second agents and thereby enhance the stability of amentoflavone.

Abstract: A surfactant-free cosmetic composition is disclosed. The composition is a stable water in silicone oil (W/S) formulation containing a silicone oil phase portion and an aqueous phase portion, wherein the silicone oil phase portion contains an emollient having a pyrrolidone carboxylic acid group, oil-absorbing powder and silicone oil, and the aqueous phase portion contains 50 wt.% or more of water based on the total weight of the surfactant-free cosmetic composition. The composition may further contain a high content of vitamin C or a vitamin C derivative and has improved long term storage stability.

Abstract: A surfactant-free cosmetic composition is disclosed. The composition is a stable water in silicone oil (W/S) formulation containing a silicone oil phase portion and an aqueous phase portion, wherein the silicone oil phase portion contains an emollient a pyrrolidone carboxylic acid group, oil-absorbing powder and silicone oil, and the aqueous phase portion contains 50 wt. % or more of water based on the total weight of the surfactant-free cosmetic composition. The composition may further contain a high content of vitamin C or a vitamin C derivative and has improved long term storage stability.

Abstract: The present invention relates to a transparent or semitransparent cosmetic composition in which the stability of amentoflavone is enhanced, and more particularly, to a transparent or semitransparent cosmetic composition, wherein a water-soluble amentoflavone-oligomer complex, in which amentoflavone is encapsulated in a hollow structure of an oligomer structure, is stabilized in a second agent containing a polyhydric alcohol, a two-liquid-type container is used to mix first and second agents before use, and hydrotrope is contained in the first agent to increase the mixing stability of the first and second agents and thereby enhance the stability of amentoflavone.

Abstract: This invention is about a novel Biomolecule Transducton Motif (BTM), Sim-2 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Sim-2 BTM. This Sim-2 BTM can be used for Drug Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.

Abstract: This invention is about a novel Biomolecule Transducton Motif (BTM), Sim-2 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Sim-2 BTM. This Sim-2 BTM can be used for Drug Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.

Abstract: This invention is about a novel Biomolecule Transduction Motif (BTM), Mph-1 peptide, which has a potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Mph-1 BTM. This Mph-1 BTM can be used for Durg Delivery System, development of new recombinant protein vaccines or DNA/RNA vaccines, gene and protein theraphy, production of pharmacologically or medicinally useful proteins or pharmacomedicinal drug therapy.